02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:43 , May 31, 2018 |  BC Innovations  |  Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
19:55 , Oct 13, 2017 |  BioCentury  |  Regulation

Expanding the HAE tool kit

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency. Two subcutaneous prophylactics that have completed Phase...
19:28 , May 18, 2017 |  BC Extra  |  Clinical News

Shire HAE treatment from Dyax deal clears Phase III hurdle

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will submit a BLA to FDA by early next year for subcutaneous lanadelumab (SHP643) to prevent hereditary angioedema attacks. The company will base its submission on data from the...
21:45 , May 12, 2017 |  BioCentury  |  Strategy

Vertical vision

Shire plc ’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to...
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
08:00 , Nov 9, 2015 |  BioCentury  |  Finance

HAE maker

The $10.5 billion shopping spree by Shire plc (LSE:SHP; NASDAQ:SHPG) in hereditary angioedema likely has come to an end, as the company expects it now has all the HAE products it needs. The final deal...
01:15 , Nov 3, 2015 |  BC Extra  |  Top Story

Shire builds on HAE franchise with Dyax takeout

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Dyax Corp. (NASDAQ:DYAX) for $37.30 per share, or $5.9 billion in cash. The price represents a 35% premium to Dyax's close of $27.53 on Oct. 30, the last trading...
08:00 , Jan 22, 2015 |  BC Innovations  |  Targets & Mechanisms

Pseudo-allergy exposed

The perpetual worry for clinicians in administering injectable drugs is the chance they will induce allergic-type reactions either at the site of injection, or systemically if given during surgery. The problem turns out to be...
07:00 , Jul 21, 2014 |  BioCentury  |  Strategy

AbbVie's plan B

Clinical setbacks and a rapidly evolving HCV landscape have left AbbVie Inc. less insulated from potential biosimilar competition for blockbuster Humira adalimumab. Now that Shire plc has decided to accept AbbVie's takeout bid, the specialty...